Research

Hormonal

Activation of SIRT1 reduces hepatic steatosis by deacetylating and inhibiting lipogenic transcription factors SREBP-1c and ChREBP, while simultaneously enhancing fatty acid beta-oxidation via PPARalpha/PGC-1alpha signaling.

SIRT1 is a metabolic sensor that helps the liver manage fat. It works by turning down fat production genes and turning up fat-burning genes. While activating SIRT1 (e.g., via calorie restriction or specific compounds) shows protective effects in animal models, it is not a standalone cure. The primary driver of fatty liver remains the imbalance of lipid acquisition (diet/alcohol) versus removal.

GoodSupportsHIGH confidence
SIRT1 activation shows beneficial effect through inhibiting lipogenesis by deacetylating SREBP-1c and ChREBP to block their downstream lipogenic genes, and increasing fatty acid beta-oxidation via deacetylating PPARalpha/PGC-1alpha, thus rebalances the hepatic lipid hemostasis.
Ren‐Bo Ding et al. · International Journal of Biological Sciences · 2017

Why this rating

Evidence is derived from multiple genetic mouse models (knockouts and overexpression) and pharmacological interventions (resveratrol, SRT1720), though human clinical trial data is not the primary focus of this review.

Source

Emerging roles of SIRT1 in fatty liver diseases

Ren‐Bo Ding et al. · International Journal of Biological Sciences · 2017

DOI 10.7150/ijbs.19370

narrative_reviewCited 358×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →